Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis

ARYB Lee, SY Wong, LYA Chai, SC Lee, MX Lee… - Bmj, 2022 - bmj.com
Objective To compare the efficacy of covid-19 vaccines between immunocompromised and
immunocompetent people. Design Systematic review and meta-analysis. Data sources …

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …

Subcutaneous REGEN-COV antibody combination to prevent Covid-19

MP O'Brien, E Forleo-Neto, BJ Musser… - … England Journal of …, 2021 - Mass Medical Soc
Background REGEN-COV (previously known as REGN-COV2), a combination of the
monoclonal antibodies casirivimab and imdevimab, has been shown to markedly reduce the …

COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

L Pagano, J Salmanton-García, F Marchesi… - Journal of hematology & …, 2021 - Springer
Background Patients with hematological malignancies (HM) are at high risk of mortality from
SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse …

A COVID-19 peptide vaccine for the induction of SARS-CoV-2 T cell immunity

JS Heitmann, T Bilich, C Tandler, A Nelde, Y Maringer… - Nature, 2022 - nature.com
T cell immunity is central for the control of viral infections. CoVac-1 is a peptide-based
vaccine candidate, composed of SARS-CoV-2 T cell epitopes derived from various viral …

[HTML][HTML] Seroconversion rates following COVID-19 vaccination among patients with cancer

A Thakkar, JD Gonzalez-Lugo, N Goradia, R Gali… - Cancer cell, 2021 - cell.com
As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically
needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we …

Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors

RT Shroff, P Chalasani, R Wei, D Pennington… - Nature medicine, 2021 - nature.com
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
shown high efficacy, but immunocompromised participants were excluded from controlled …

[HTML][HTML] BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel

T Brosh-Nissimov, E Orenbuch-Harroch… - Clinical Microbiology …, 2021 - Elsevier
Objectives The mRNA coronavirus disease 2019 (COVID-19) vaccines have shown high
effectiveness in the prevention of symptomatic COVID-19, hospitalization, severe disease …

Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies

LM Greenberger, LA Saltzman, JW Senefeld… - Cancer cell, 2021 - cell.com
The mRNA vaccines BNT162b2 and mRNA-1273 have robust safety and efficacy against
COVID-19 among immunocompetent individuals (Creech et al., 2021). However, many …

Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study

A Fendler, STC Shepherd, L Au, KA Wilkinson, M Wu… - Nature cancer, 2021 - nature.com
Abstract Coronavirus disease 2019 (COVID-19) antiviral response in a pan-tumor immune
monitoring (CAPTURE)(NCT03226886) is a prospective cohort study of COVID-19 immunity …